The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The results aren’t all positive – Trelegy wasn’t able to improve on Relvar/Breo when it came to reducing asthma exacerbations and two other doses of Trelegy didn’t perform better than the ...

GlaxoSmithKline and partner Innoviva are seeking an expansion to the US label of their Trelegy Ellipta lung drug ... Relvar (fluticasone+vilanterol) and Anoro (umeclidinium+vilanterol).